AbCellera Biologics financials
$14.82+6.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $75.1M | $28.8M | $38.0M | $485.4M | $375.2M | $233.2M |
| Gross profit | $75.1M | $28.8M | $38.0M | $485.4M | $375.2M | $233.2M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$217.1M | -$314.8M | -$237.2M | $216.5M | $204.4M | $156.0M |
| Net income | -$146.4M | -$162.9M | -$146.4M | $158.5M | $153.5M | $85.1M |
| Net margin | −194.9% | −564.8% | −385.0% | 32.7% | 40.9% | 36.5% |
| Diluted EPS | $-0.49 | $-0.55 | $-0.51 | $0.50 | $0.48 | $0.45 |
| EBITDA | -$198.7M | -$302.2M | -$224.4M | $244.4M | $221.7M | $160.9M |
| Operating cash flow | -$131.3M | -$108.6M | -$43.9M | $277.4M | $244.6M | $22.7M |
| Free cash flow | -$174.1M | -$187.0M | -$120.8M | $206.7M | $186.1M | $13.0M |
| Diluted shares | 298.7M | 294.3M | 289.2M | 314.8M | 318.3M | 263.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $128.5M | $156.3M | $133.3M | $386.5M | $476.1M | $594.1M |
| Short-term investments | $405.3M | $469.3M | $627.3M | $499.9M | $246.8M | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.36B | $1.36B | $1.49B | $1.54B | $1.32B | $1.01B |
| Total liabilities | $390.0M | $304.5M | $335.8M | $307.6M | $292.8M | $175.0M |
| Shareholders' equity | $966.9M | $1.06B | $1.15B | $1.23B | $1.03B | $830.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology